Aurore Perrot, MD, PhD, University Hospital Antwerp, Vandoeuvre-lès-Nancy, France, discusses the CASSIOPEIA study (NCT02541383) evaluating the use of daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTD) in autologous transplant-eligible newly-diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
CASSIOPEIA: D-VTD in high-risk multiple myeloma
Теги
Speaker: Aurore PerrotInstitution: University Hospital AntwerpEvent: VJVirtualEvent: EBMT 2020Format: InterviewSubject: Multiple MyelomaField: TransplantationField: Trial UpdatesField: TreatmentField: Immuno-OncologyMedicines: DaratumumabMedicines: BortezomibMedicines: ThalidomideMedicines: DexamethasoneMedicines: AntibodiesTrial: CASSIOPEIANCT02541383Field: MRD
